dacarbazine has been researched along with dactolisib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bachoo, R; Burma, S; Gao, X; Gil del Alcazar, CR; Habib, AA; Hardebeck, MC; Li, L; Mukherjee, B; Tomimatsu, N; Xie, XJ; Yan, J | 1 |
| Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G | 1 |
3 other study(ies) available for dacarbazine and dactolisib
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Blood-Brain Barrier; Catalytic Domain; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Glioblastoma; Humans; Imidazoles; Mice; Mice, Transgenic; Phosphoinositide-3 Kinase Inhibitors; Protein Interaction Domains and Motifs; Quinolines; Radiation-Sensitizing Agents; Temozolomide; TOR Serine-Threonine Kinases | 2014 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glioma; Humans; Imidazoles; Inhibitory Concentration 50; Male; Mice, SCID; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |